Mobile

Detecting early pre-symptomatic psoriatic arthritis in patients with skin moderate or severe psoriasis - how effective is ustekinumab (Stelara) in limiting joint disease progression and future disabil...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-002640-25

Detecting early pre-symptomatic psoriatic arthritis in patients with skin moderate or severe psoriasis - how effective is ustekinumab (Stelara) in limiting joint disease progression and future disability?

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Do the imaging features of subclinical enthesopathy (the earliest change seen in psoriatic arthritis), as measured by peripheral joint ultrasound (USS) and whole body MRI, in patients with moderate-to-severe psoriasis (PASI>10), change when treated for 24 weeks with ustekinumab (at standard dose) for their psoriatic skin disease?

Critère d'inclusion

  • Psoriatic disease (psoriasis and psoriatic arthritis)

Liens